Clinical Trial

JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This Phase 1 first-in-human study will investigate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of JZP898 monotherapy as well as JZP898 in combination with pembrolizumab in adult participants with advanced or metastatic solid tumors.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2023-10-26; most recent amendment 2025-12-08.
Status change: Not Yet Recruiting → Recruiting 2023-11-17
Trial Details
NCT Number NCT06108050
Lead Sponsor Jazz Pharmaceuticals
Collaborators: Merck Sharp & Dohme LLC
Conditions Advanced Solid Tumor, Metastatic Solid Tumor
Enrollment 177 participants
Start Date 2023-11-07
Primary Completion 2027-11-30 (estimated)
Study Completion 2028-05-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-16